Rosetta Genomics Ltd.

Equities

ROSGQ

IL0011026494

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:34:46 2024-02-12 am EST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2018	Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	CI
2018	Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index	CI

Rosetta Genomics Ltd. Enters into an Exclusive Distribution Agreement with Rhenium Ltd. for RosettaGX Reveal in Israel

September 29, 2016 at 10:54 am EDT

Rosetta Genomics Ltd. announced that the company has entered into an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of RosettaGX Reveal™ (Reveal), the company’s microRNA classifier for indeterminate thyroid nodules, in Israel. Under the terms of the agreement, Rhenium’s exclusivity is contingent on Rhenium meeting certain volume commitments.

Latest news about Rosetta Genomics Ltd.

Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	18-05-30	CI
Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index	18-05-21	CI
Rosetta Genomics Ltd. Announces Resignation of Ken Berlin as President and CEO, Effective April 18, 2018	18-04-10	CI
Genoptix, Inc. and Rosetta Genomics Ltd. Enter into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide	18-03-13	CI
Genoptix, Inc. completed the acquisition of PDx Business of Rosetta Genomics Ltd..	18-03-01	CI
Genoptix, Inc. entered into a definitive agreement to acquire PDx Business of Rosetta Genomics Ltd. for $1 million.	18-02-26	CI
Genoptix, Inc. entered into a merger agreement to acquire Rosetta Genomics Ltd. for $8 million.	18-02-26	CI
Genoptix, Inc. cancelled the proposed acquisition of Rosetta Genomics Ltd..	18-02-21	CI
Genoptix, Inc. entered into a term sheet agreement to acquire Rosetta Genomics Ltd..	17-12-14	CI
Rosetta Genomics Ltd. Announces Resignation of David Sidransky as Director	17-11-14	CI
Certain Ordinary Shares of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	17-11-01	CI
Certain Stock Options of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	17-11-01	CI
Certain Warrants of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	17-11-01	CI
Certain Restricted Stock Units of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	17-11-01	CI
Pragmin Prognosis cancelled the acquisition of CYNOGEN Inc. from Rosetta Genomics Ltd..	17-10-15	CI
Rosetta Genomics Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-10-10	CI
Rosetta Genomics Is Considering Options To Sell Pragmin	17-10-10	CI
Rosetta Genomics Ltd. announced that it has received $2 million in funding	17-10-01	CI
Rosetta Genomics Ltd. announced that it expects to receive $2 million in funding	17-09-27	CI
Pragmin Prognosis entered into a definitive agreement to acquire CYNOGEN Inc. from Rosetta Genomics Ltd. for $2.9 million.	17-09-07	CI
Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice	17-08-21	CI
Rosetta Genomics Ltd. Enters Collaboration with Meir Medical Center to Develop a microRNA Classifier Relating to Patients with Non Small Cell Lung Cancer Considered for Treatment with Immuno oncology Drugs	17-05-23	CI
Rosetta Genomics Receives Inquiries For PersonalizeDx Business	17-05-22	CI
Rosetta Genomics Mulls Acquisitions	17-05-08	CI
Rosetta Genomics Signs an Exclusive Distribution Agreement with Cytolog Laboratories	17-05-05	CI

Chart Rosetta Genomics Ltd.

Duration

Period

More charts

Company Profile

Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ROSETTA GENOMICS LTD.	-.--%	592
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research